CPCeleste Porsbjerg

Celeste Porsbjerg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Celeste Porsbjerg has a total of 798 co-authors. Here are the top co-authors by number of shared publications:

  • Vibeke Backer

    Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University , Copenhagen

    31 shared publications
  • Vibeke Backer

    Department of Otorhinolaryngology, Head & Neck Surgery, and Audiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark

    24 shared publications
  • Asger Sverrild

    Respiratory Research Unit, Department of Respiratory and Infectious Disease, Bispebjerg University Hospital, Copenhagen, Denmark

    13 shared publications
  • V. Backer

    Department of Respiratory Medicine L, Bispebjerg Hospital and University of Copenhagen, Copenhagen, Denmark

    11 shared publications
  • Charlotte Suppli Ulrik

    Department of Respiratory Medicine, Copenhagen University Hospital - Hvidovre, Hvidovre, Denmark

    8 shared publications
  • Morten Hvidtfeldt

    Respiratory Research Unit, Department of Respiratory and Infectious Diseases Bispebjerg University Hospital Copenhagen Denmark

    8 shared publications

Latest Publications

  • Clustering of the Bronchial Epithelial Immune Response to Viral Stimulation in Patients With Asthma Identifies Clinically Recognisable Epithelial Exacerbation Response Profiles

    by Laurits Frøssing, Morten Hvidtfeldt, Juan Jose Nieto‐Fontarigo, Sangeeta Ramu, Mandy Menzel, Lise Lotte Eriksen, Nanna Dyhre‐Petersen, Asger Sverrild, Lena Uller, Celeste Porsbjerg

    Summary: Clustering of bronchial epithelial immune responses to a viral mimic identifies distinct immune response patterns. Induction of epithelial alarmins differs markedly, with only TSLP being associated with severe eosinophilic disease.

  • Open Access

    Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial

    by Celeste Porsbjerg, Eleanor M Dunican, Njira L Lugogo, Mario Castro, Alberto Papi, Vibeke Backer, Christopher E Brightling, Arnaud Bourdin, J Christian Virchow, Mei Zhang, et al.

    Rationale: Chronic mucus hypersecretion contributes to airway obstruction in asthma. Objectives: To assess dupilumab efficacy by baseline mucus plug score. Methods: In VESTIGE (NCT04400318), adults with moderate-to-severe asthma, baseline blood eosinophils ≥300 cells/μL, and fractional exhaled nitric oxide (FeNO) ≥25 ppb received dupilumab 300 mg (n = 72) or placebo (n = 37) every 2 weeks for 24 weeks. Post hoc analyses included mucus plug score change from baseline, and patient proportion achieving FeNO <25 ppb, percent predicted FEV1, and FVC stratified by baseline mucus plug score (high/low defined by score ≥4 or 0-3.5, respectively, derived from high-resolution computed tomography scans). Measurements and Main Results: Fewer dupilumab-receiving patients had high mucus plug score at week 24 than at baseline (32.8% vs 67.2%); proportions remained similar in placebo-receiving patients (76.7% vs 73.3%). Dupilumab versus placebo recipients were more likely to achieve FeNO <25 ppb in high-/low-mucus-plug score subgroups (odds ratio, 6.64; P = .003/8.54; P = .024). Dupilumab versus placebo significantly increased pre-/post-bronchodilator percent predicted FEV1 (least squares mean difference [LSMD], 16.77 percentage points [95% CI, 9.81-23.73]; P <.0001 [pre] and 12.70 [95% CI, 3.87-21.52]; P = .0055 [post]) and pre-bronchodilator FVC (LSMD, 0.42 mL [95% CI, 0.17-0.66]; P = .001), and numerically improved post-bronchodilator FVC (LSMD, 0.30 mL [95% CI, 0.01-0.59]; P = .0399) in the high-mucus-plug score subgroup. Conclusions: Dupilumab reduced mucus plug scores and improved lung function in patients with moderate-to-severe asthma with high baseline mucus plug score, and increased the likelihood of achieving FeNO <25 ppb regardless of baseline mucus plug score.


  • Open Access

    Long‐Term, Real‐World Effectiveness of Allergen Immunotherapy in Children and Adolescents With Allergic Rhinitis and Asthma

    by Christian Woehlk, Thomas Stranzl, Marco Contoli, Nick Freemantle, Andreas Kallsoy Slaettanes, Julie Rask Larsen, Celeste Porsbjerg, Benedikt Fritzsching

    Background: Respiratory allergies often begin in childhood and can progress over time, leading to increased disease burden. Allergen immunotherapy (AIT) is the only causal treatment for allergic respiratory diseases with disease‐modifying potential. While randomised trials support its efficacy in controlling allergic rhinitis (AR) and asthma symptoms, long‐term real‐world data in children remain limited. Methods: This paediatric study ( n = 11,036) was conducted within the pre‐defined framework of the REACT study, based on protocol‐specified objectives. Children (< 18 years) with physician‐diagnosed AR, with or without pre‐existing asthma, were included. AIT‐treated patients were matched 1:1 to non‐AIT controls. Effectiveness was assessed over 9 years by comparing AR and asthma medication prescriptions, using a public database covering all reimbursable AIT products. Relative differences were calculated across the full observation period. Results: AIT‐treated children (mean age 11.4 years; 62.1% male) exhibited greater reductions in AR medication use than controls (additional 9% reduction beyond 61% in controls). In children with asthma, AIT was associated with additional reductions in asthma medication use (−21% beyond −48% in controls), severe exacerbations (−21% beyond −36%), and new oral corticosteroid prescriptions (−33% beyond −41%). Age stratification revealed more pronounced AR medication reductions in younger children (0–11 years) than in adolescents (12–17 years). Conclusion: This large‐scale, real‐world study supports the long‐term effectiveness of AIT in children with AR, with or without asthma. The findings reflect improved disease control and suggest a disease‐modifying effect of AIT. Early intervention, particularly in younger children, may help mitigate the progression of allergic disease.


  • Reframing remission in severe asthma: a conceptual framework for distinguishing disease activity versus damage

    by Celeste Porsbjerg, Hitasha Rupani, John D Brannan, Shigeharu Ueki, Martijn C Nawijn, Jonas S Erjefält, Pascal Chanez, Gary P Anderson, Ian D Pavord


  • Open Access

    Burden of Oral Corticosteroid Use in Severe Asthma: Challenges and Opportunities

    by G. Walter Canonica, Celeste Porsbjerg, David B. Price, Michael E. Wechsler, Liam G. Heaney, Nicola A. Hanania, Rebecca Gall, Nami Pandit‐Abid, Juby A. Jacob‐Nara, Harry J. Sacks

    Over the past 70 years, oral corticosteroids (OCS) have played an important role in the management of acute and chronic asthma; however, their use is associated with an increased incidence of adverse events, chronic diseases such as osteoporosis and diabetes, and mortality, as well as increased healthcare resource utilization and costs. Despite a consensus that the use of OCS should be minimized in asthma treatment strategies, many patients still routinely receive long‐term or frequent short courses of OCS. Add‐on biologics can help to improve asthma control in patients with severe asthma and evidence of type 2 inflammation; in clinical trials and real‐world studies, both short‐ and long‐term OCS‐sparing effects have been demonstrated. In this review, we discuss the benefits and burdens of OCS in patients with severe asthma from the perspective of both patients and healthcare providers and outline potential methods for reducing reliance on OCS. Given the risk of adrenal insufficiency or crisis upon cessation of OCS, we discuss the need for clear guidance and algorithms for the tapering of OCS together with the requirement for multidisciplinary patient–provider interactions as part of an effective OCS stewardship scheme.


  • Open Access

    Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register

    by Susanne Hansen, Kjell Erik Julius Håkansson, Marianne Baastrup Soendergaard, Anne-Sofie Bjerrum, Johannes Martin Schmid, Sofie Lock Johansson, Linda Makowska Rasmussen, Claus Rikard Johnsen, Anna von Bülow, Barbara Bonnesen, et al.


  • Open Access

    International Severe Asthma Registry (ISAR): 2017–2024 Status and Progress Update

    by Désirée Larenas-Linnemann, Chin Kook Rhee, Alan Altraja, John Busby, Trung N. Tran, Eileen Wang, Todor A. Popov, Patrick D. Mitchell, Paul E. Pfeffer, Roy Alton Pleasants, et al.

    The International Severe Asthma Registry (ISAR) was established in 2017 to advance the understanding of severe asthma and its management, thereby improving patient care worldwide. As the first global registry for adults with severe asthma, ISAR enabled individual registries to standardize and pool their data, creating a comprehensive, harmonized dataset with sufficient statistical power to address key research questions and knowledge gaps. Today, ISAR is the largest repository of real-world data on severe asthma, curating data on nearly 35,000 patients from 28 countries worldwide, and has become a leading contributor to severe asthma research. Research using ISAR data has provided valuable insights on the characteristics of severe asthma, its burdens and risk factors, real-world treatment effectiveness, and barriers to specialist care, which are collectively informing improved asthma management. Besides changing clinical thinking via research, ISAR aims to advance real-world practice through initiatives that improve registry data quality and severe asthma care. In 2024, ISAR refined essential research variables to enhance data quality and launched a web-based data acquisition and reporting system (QISAR), which integrates data collection with clinical consultations and enables longitudinal data tracking at patient, center, and population levels. Quality improvement priorities include collecting standardized data during consultations and tracking and optimizing patient journeys via QISAR and integrating primary/secondary care pathways to expedite specialist severe asthma management and facilitate clinical trial recruitment. ISAR envisions a future in which timely specialist referral and initiation of biologic therapy can obviate long-term systemic corticosteroid use and enable more patients to achieve remission.


  • Open Access

    The impact of biologic therapy on work capacity and workforce attachment in patients with severe asthma

    by Kjell Erik Julius Håkansson, Rikke Ibsen, Niels Steen Krogh, Marianne Baastrup Soendergaard, Susanne Hansen, Anne-Sofie Bjerrum, Anna von Bülow, Ole Hilberg, Anders Løkke, Barbara Bonnesen, et al.

    IntroductionSevere asthma impacts work capacity, but little is known about the effects of biologic therapy on patients' ability to work. We aimed to assess the impact of biologic therapy for severe asthma on work capacity and workforce attachment.MethodsThis cohort study used the Danish Severe Asthma Register, comprising all Danish patients with severe asthma initiating biologic therapy. Earned income, hours worked, and workforce attachment tracked in national databases from one year prior to biologic therapy as well as during two years of biologic therapy. Outcomes were compared to age-, sex-, cohabitation- and residence-matched controls from the general population.ResultsOverall, 381 patients aged 20-62 years (52% females) were included. Annual weeks worked were lower among patients with severe asthma (adjusted incidence rate ratio (aIRR) 0.82 (0.80-0.84)), driven by increases in sick-leave (aIRR 2.77 (2.58-2.98)), unemployment (aIRR 1.38 (1.30-1.46)) and disability pension (aIRR 1.85 (1.76-1.94)).After initiating biologic therapy, patients saw modest increases in annual hours worked during the second year of treatment (aIRR 1.03 (1.03-1.04)). However, patients remained at risk for temporary (OR 1.83 (1.15-2.93)) and permanent (OR 2.67 (1.16-6.16)) workforce withdrawal.Patients achieving on-treatment remission worked significantly more hours compared to non- and clinical responders and had lower unemployment-, sick-leave and disability pension rates both at baseline and after two years.ConclusionBiologic therapy resulted in a modest increase in hours worked, yet patients remain at significant risk of early workforce withdrawal. Patients achieving remission had a stronger attachment to the workforce, also prior to biologic therapy.


  • Early Reduction of FeNO on Anti‐ IL5 Biologics Is Associated With Clinical Remission of Severe Asthma

    by Marianne Baastrup Soendergaard, Susanne Hansen, Kjell Erik Julius Håkansson, Anna von Bülow, Anne‐Sofie Bjerrum, Johannes Martin Schmid, Sofie Lock Johansson, Linda Makowska Rasmussen, Claus Rikard Johnsen, Barbara Bonnesen Bertelsen, et al.

    Background: In patients with severe asthma, treatment with anti‐interleukin‐5 (IL‐5) biologics can lead to a reduction in fractional exhaled nitric oxide (FeNO) in some patients. The clinical implications of varying FeNO responses to anti‐IL‐5 biologics remain unclear. This study aims to categorise patients based on their FeNO response to anti‐IL‐5 biologics and evaluate the association of these categories with clinical outcomes. Methods: We used the Danish Severe Asthma Register (DSAR) to identify the early FeNO response profiles in patients receiving anti‐IL5 biologics. We defined FeNO responders as patients with elevated FeNO levels at baseline and a decrease corresponding to the minimal clinically important difference (MCID) at 4 months of follow‐up and FeNO non‐responders as those who did not experience a decrease. Results: We identified 403 patients on anti‐IL5 treatment in DSAR, and 265 (66%) had elevated FeNO levels at baseline. After 4 months of treatment, 151 (57%) patients showed a significant decrease in FeNO levels, and 114 (43%) did not. FeNO responders were more likely to achieve clinical remission of asthma (34% vs. 19%, p = 0.01, OR 2.11, CI 1.04, 5.18, p = 0.03) than FeNO non‐responders after 12 months of treatment. The higher remission rates in FeNO responders mainly reflected a higher rate of normalisation of lung function. Conclusions: FeNO levels were reduced after anti‐IL5 treatment in a significant proportion of patients treated with anti‐IL5, and this was associated with clinical remission. Early FeNO response to anti‐IL5 could potentially be used as a biomarker to guide management decisions with biologics towards remission of disease in severe asthma.


  • Dupilumab reduces mucus plugging and volume: phase 4 VESTIGE trial

    by Celeste Michala Porsbjerg, Eleanor Dunican, Njira L Lugogo, Mario Castro, Alberto Papi, Nina Vibeke Backer, Christopher E Brightling, Arnaud Bourdin, Johann Christian Virchow, Mei Zhang, et al.

    Introduction: Mucus hypersecretion resulting from type 2 inflammatory cytokines (e.g., interleukin [IL]-13) drives intermittent airway obstruction and remodelling. Dupilumab blocks the IL-4/13 receptor, improves lung function, and reduces rates of severe exacerbations in patients with asthma, with an acceptable safety profile. The VESTIGE study (NCT04400318) assessed dupilumab impact on airway mucus plugging and volume, inflammation, and lung function. Methods: Patients (21-70 years) with uncontrolled moderate-to-severe asthma, elevated type 2 biomarkers (baseline blood eosinophil count≥300 cells/µL; fractional exhaled nitric oxide [FeNO]≥25 ppb), pre-bronchodilator percent predicted forced expiratory volume in 1 second (pre-BD ppFEV1)≤80%, and ≥1 exacerbation year prior were randomized 2:1 to add-on dupilumab 300 mg (N=72) or matched placebo (PBO, N=37) q2w for 24 weeks. We quantified occluded bronchopulmonary segments to give mucus plug scores (0–20). Voxels per mucus plug, measured by CT, gave mucus volumes. We also assessed FeNO and pre-BD ppFEV1 at Week 24. Results: The dupilumab group had reduced mucus scores (least squares mean difference [LSMD][SE] from baseline:–4.9 [0.8] points vs PBO; nominal P <0.001) and volumes (–0.11 [0.02] mL; nominal P <0.001), were 9.8 times more likely to achieve FeNO<25 ppb (P <0.001), and improved in pre-BD ppFEV1 (LSMD[SE]: 13.8 [3.1] %, nominal P <0.001). Improvements from baseline to Week 24 in pre-BD ppFEV1 correlated with lower mucus score in the dupilumab group (Pearson’s correlation coefficient: –0.61 (P <0.0001)). Conclusion: Dupilumab treatment led to reductions in airway mucus plugging, mucus volume, and inflammation, likely contributing to improved lung function.